| |  Online-Ressource |
|---|
| Verfasst von: | Berger, Anne Katrin [VerfasserIn]  |
|---|
| | Abel, Ulrich [VerfasserIn] |
|---|
| | Kloor, Matthias [VerfasserIn] |
|---|
| | Ose, Jennifer [VerfasserIn] |
|---|
| | Weber, Tim [VerfasserIn] |
|---|
| | Stange, Annika [VerfasserIn] |
|---|
| | Haag, Georg Martin [VerfasserIn] |
|---|
| | Haberkorn, Uwe [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| Titel: | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer |
|---|
| Titelzusatz: | the Heidelberg REMOTUX trial |
|---|
| Verf.angabe: | Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
|---|
| E-Jahr: | 2012 |
|---|
| Jahr: | 22 March 2012 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 25.04.2018 |
|---|
| Titel Quelle: | Enthalten in: BMC cancer |
|---|
| Ort Quelle: | London : BioMed Central, 2001 |
|---|
| Jahr Quelle: | 2012 |
|---|
| Band/Heft Quelle: | 12(2012) Artikel-Nummer 108, 6 Seiten |
|---|
| ISSN Quelle: | 1471-2407 |
|---|
| Abstract: | The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes. |
|---|
| DOI: | doi:10.1186/1471-2407-12-108 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1186/1471-2407-12-108 |
|---|
| | kostenfrei: Volltext: https://doi.org/10.1186/1471-2407-12-108 |
|---|
| | DOI: https://doi.org/10.1186/1471-2407-12-108 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | 18F-FDG PET CT |
|---|
| | Cetuximab |
|---|
| | Colorectal cancer |
|---|
| | Metabolic imaging |
|---|
| | Metastases |
|---|
| K10plus-PPN: | 1572358572 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬A¬ phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer / Berger, Anne Katrin [VerfasserIn]; 22 March 2012 (Online-Ressource)
